Lisanti Capital Growth LLC bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 4th quarter, HoldingsChannel reports. The institutional investor bought 8,455 shares of the company’s stock, valued at approximately $656,000.

Other large investors have also bought and sold shares of the company. The Manufacturers Life Insurance Company increased its holdings in Neurocrine Biosciences by 7.8% in the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock valued at $123,000 after buying an additional 193 shares during the last quarter. Crow Point Partners LLC purchased a new position in Neurocrine Biosciences in the fourth quarter valued at $145,000. M&T Bank Corp purchased a new position in Neurocrine Biosciences in the fourth quarter valued at $202,000. Comerica Bank purchased a new position in Neurocrine Biosciences in the third quarter valued at $210,000. Finally, Ardsley Advisory Partners purchased a new position in Neurocrine Biosciences in the second quarter valued at $230,000.

In other Neurocrine Biosciences news, insider Darin Lippoldt sold 9,900 shares of the company’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $73.05, for a total value of $723,195.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gary A. Lyons sold 10,000 shares of the company’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $72.92, for a total transaction of $729,200.00. Following the completion of the transaction, the director now owns 272,066 shares of the company’s stock, valued at approximately $19,839,052.72. The disclosure for this sale can be found here. Insiders sold 189,707 shares of company stock valued at $14,975,715 in the last 90 days. 4.80% of the stock is currently owned by insiders.

Several equities analysts recently commented on NBIX shares. Jefferies Group increased their target price on Neurocrine Biosciences to $105.00 and gave the company a “buy” rating in a report on Friday, January 5th. BidaskClub raised Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, January 4th. Oppenheimer set a $85.00 target price on Neurocrine Biosciences and gave the company a “buy” rating in a report on Tuesday, December 12th. Robert W. Baird reissued a “buy” rating and issued a $84.00 target price on shares of Neurocrine Biosciences in a report on Friday, November 3rd. Finally, Needham & Company LLC reissued a “buy” rating and issued a $86.00 target price on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. One investment analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Neurocrine Biosciences has a consensus rating of “Buy” and a consensus target price of $84.13.

Neurocrine Biosciences, Inc. (NBIX) opened at $79.28 on Friday. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences, Inc. has a 12 month low of $39.21 and a 12 month high of $91.82.

TRADEMARK VIOLATION WARNING: This report was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://theolympiareport.com/2018/02/11/8455-shares-in-neurocrine-biosciences-inc-nbix-acquired-by-lisanti-capital-growth-llc.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.